Results 161 to 170 of about 2,296,903 (345)

A shared vision on user experiences, on mics, merves, Madonna and more [PDF]

, 2012
This workshop introduces the Envisioning Use technique which is aimed at generating a shared vision on user experiences in product development teams. This shared vision could support decision making with regard to user experiences and inspire solution ...
Bijl-Brouwer, Mieke van der, Boess, Stella   +1 more
core   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Call for shared decision making in Iran; Future directions [PDF]

Journal of Analytical Research in Clinical Medicine, 2017
Samira Abbasgholizadeh-Rahimi
doaj   +1 more source

Shared decision making during antenatal counselling for anticipated extremely preterm birth [PDF]

, 2018
Conor Barker, Sandra Dunn, Gregory P. Moore, Jessica Reszel, Brigitte Lemyre, Thierry Daboval   +5 more
openalex   +1 more source

The issue of design in managerial decision making [PDF]

, 2009
It is argued that the design of decisions is a process that in many ways is shaped by social factors such as identities, values, and influences. To be able to understand how these factors impact organizational decisions, the focus must be set on the ...
Patokorpi, Erkki, Selart, Marcus
core  

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

Molecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn   +11 more
wiley   +1 more source

Predictors of Family Dissatisfaction with Support During Neurocritical Care Shared Decision-Making [PDF]

, 2021
Urs Weber, Qiang Zhang, Derek Ou, James Garritano, Jennifer Johnson, Nathanial Anderson, Andrea Knies, Belinda Nhundu, Cynthia Bautista, Kevin Huang, Ana‐Maria Vranceanu, Jonathan Rosand, David Y. Hwang   +12 more
openalex   +1 more source

Patient's perception of autonomy support and shared decision making in physical therapy [PDF]

, 2015
DE VRIENDT, PATRICIA, Deveugele, Myriam, Devisch, Ignaas, Dierckx, Katreine, Vandevelde, Dominique   +4 more
core   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source